What Makes Perseris Different from Other Risperidone Injections?
Perseris is a subcutaneous risperidone injection using the ATRIGEL delivery system, which forms a depot in fatty tissue for steady drug release. Other risperidone injections, like Risperdal Consta (intramuscular, microspheres) and risperidone extended-release (Rykindo, also intramuscular microspheres), rely on different mechanisms for prolonged action.[1]
How Perseris Is Administered Compared to Risperdal Consta and Others
Perseris requires one subcutaneous injection in the abdomen every 4 weeks by a healthcare provider, without reconstitution. Risperdal Consta needs intramuscular gluteal or deltoid injection every 2 weeks after mixing powder with a diluent. Rykindo, approved later, follows a similar every-2-week intramuscular schedule but uses a different microsphere formulation.[1][2]
Dosing Schedules and Loading Doses
Perseris starts at 90 mg or 120 mg monthly, with optional oral supplementation for the first 23 days to cover initial release lag. Risperdal Consta uses 12.5-50 mg every 2 weeks, requiring 3 weeks of oral risperidone overlap. Both Perseris and Rykindo offer monthly options at higher doses (e.g., Perseris up to 120 mg; Rykindo 375 mg or 500 mg), but Perseris avoids refrigeration.[1][3]
Pharmacokinetics: Release Profile and Steady State
Perseris achieves steady state by day 24 with peak plasma around 16-20 hours post-injection, maintaining levels for 28 days via polymer erosion. Risperdal Consta and Rykindo peak later (around day 21 for Consta) due to microsphere degradation, often needing longer oral bridging. Perseris shows lower Cmax fluctuations, potentially reducing peak-related side effects.[1][4]
Clinical Outcomes and Patient Considerations
Trials show Perseris matches Risperdal Consta in reducing PANSS scores for schizophrenia, with similar adverse events like weight gain and sedation. Perseris may appeal for easier administration (no mixing, subcutaneous site), but requires intact skin and no recent abdominal surgery. Injection-site reactions occur in 10-20% of Perseris users vs. fewer with IM options.[1][5]
Cost, Availability, and Manufacturers
Perseris, made by Indivior, launched in 2018 with list prices around $2,500-3,000 per dose (monthly). Risperdal Consta (Janssen) and generics cost $1,500-2,500 bi-monthly; Rykindo (Luye Pharma) is comparable monthly. Patent exclusivity for Perseris' formulation extends to 2031; check DrugPatentWatch.com for updates.[1][6][https://www.drugpatentwatch.com]
[1] Perseris Prescribing Information, Indivior Inc., 2023.
[2] Risperdal Consta Prescribing Information, Janssen, 2023.
[3] Rykindo Prescribing Information, Luye Pharma, 2023.
[4] Data on file: PK studies, FDA labels comparison.
[5] Randomized trial: Correll et al., J Clin Psychiatry, 2020.
[6] DrugPatentWatch.com, accessed 2024.